Langerhans cell histiocytosis: intrinsic immunoediting
properties

a 2015

Langerhans cell histiocytosis: intrinsic immunoediting properties

KŘENOVÁ, Zdenka, Eliška TVRDÍKOVÁ, Jaroslav ŠTĚRBA, Daniela KODYTKOVÁ, Leoš KŘEN et. al.

Základní údaje

Originální název

Langerhans cell histiocytosis: intrinsic immunoediting properties

Autoři

KŘENOVÁ, Zdenka (203 Česká republika, garant, domácí), Eliška TVRDÍKOVÁ (203 Česká republika, domácí), Jaroslav ŠTĚRBA (203 Česká republika, domácí), Daniela KODYTKOVÁ (203 Česká republika, domácí) a Leoš KŘEN (203 Česká republika, domácí)

Vydání

XXV. Konference dětských hematologů a onkologů České a Slovenské republiky, 2015

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/15:00085104

Organizační jednotka

Lékařská fakulta

ISBN

978-80-210-7958-8

Klíčová slova anglicky

langerhans cell histiocytosis; non-classical immunomodulatory molecules; intrinsic immunoediting properties

Štítky

EL OK

Změněno: 7. 12. 2015 14:58, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Non-classical HLA-molecules physiologically protect the fetus from maternal allorecognition, this mechanism seems to be used by some tumors during their development. PD-L1 is physiologically expressed mainly on antigen presenting cells, some types of tumors use this ligand to supress host immune reactions. The expression of non-classical immunomodulatory molecules (HLA-G, HLA-E, HLA-F) as well as the expression of immune checkpoint regulator programmed death ligand (PD-L1) is not characterized in Langerhans cell histiocytosis (LCH). Our data suggest that non-classical immunomodulatory molecules and immune checkpoint molecules may play role in immunoediting process during development of LCH. Further studies regarding immunoediting properties including non-classical HLA molecules and immune checkpoints ligands appear warranted for better understanding and therapy of this enigmatic disorder.

Citovat

KŘENOVÁ, Zdenka, Eliška TVRDÍKOVÁ, Jaroslav ŠTĚRBA, Daniela KODYTKOVÁ a Leoš KŘEN. Langerhans cell histiocytosis: intrinsic immunoediting properties. In XXV. Konference dětských hematologů a onkologů České a Slovenské republiky. 2015. ISBN 978-80-210-7958-8.

@proceedings{1320366,
   author = {Křenová, Zdenka and Tvrdíková, Eliška and Štěrba, Jaroslav and Kodytková, Daniela and Křen, Leoš},
   booktitle = {XXV. Konference dětských hematologů a onkologů České a Slovenské republiky},
   keywords = {langerhans cell histiocytosis; non-classical immunomodulatory molecules; intrinsic immunoediting properties},
   language = {eng},
   isbn = {978-80-210-7958-8},
   title = {Langerhans cell histiocytosis: intrinsic immunoediting properties},
   year = {2015}
}

TY  - CONF
ID  - 1320366
AU  - Křenová, Zdenka - Tvrdíková, Eliška - Štěrba, Jaroslav - Kodytková, Daniela - Křen, Leoš
PY  - 2015
TI  - Langerhans cell histiocytosis: intrinsic immunoediting properties
SN  - 9788021079588
KW  - langerhans cell histiocytosis
KW  - non-classical immunomodulatory molecules
KW  - intrinsic immunoediting properties
N2  - Non-classical HLA-molecules physiologically protect the fetus from maternal allorecognition, this mechanism seems to be used by some tumors during their development. PD-L1 is physiologically expressed mainly on antigen presenting cells, some types of tumors use this ligand to supress host immune reactions. The expression of non-classical immunomodulatory molecules (HLA-G, HLA-E, HLA-F) as well as the expression of immune checkpoint regulator programmed death ligand (PD-L1) is not characterized in Langerhans cell histiocytosis (LCH). Our data suggest that non-classical immunomodulatory molecules and immune checkpoint molecules may play role in immunoediting process during development of LCH. Further studies regarding immunoediting properties including non-classical HLA molecules and immune checkpoints ligands appear warranted for better understanding and therapy of this enigmatic disorder.
ER  -

KŘENOVÁ, Zdenka, Eliška TVRDÍKOVÁ, Jaroslav ŠTĚRBA, Daniela KODYTKOVÁ a Leoš KŘEN. Langerhans cell histiocytosis: intrinsic immunoediting properties. In \textit{XXV. Konference dětských hematologů a onkologů České a Slovenské republiky}. 2015. ISBN~978-80-210-7958-8.

Podrobný výpis o publikaci